BD (Becton, Dickinson and Company) has signed a definitive agreement to acquire Accuri Cytometers, a Michigan-based company that develops and manufactures personal flow cytometers for researchers.
The acquisition would expand BD’s presence into the emerging affordable personal flow cytometer space.
The aquisition would also help expand the use of flow technology by researchers in developing regions where ease of use is critical, as well as by researchers in scientific disciplines that have not traditionally used flow cytometry, such as environmental studies.
BD president and chief operating officer Vincent Forlenza said Accuri Cytometers’ offering of flow cytometers for a new audience of researchers will complement and broaden BD’s current offerings for life scientists.
"We believe that, once completed, this acquisition will enable BD to further contribute to medical and scientific advances, in line with our corporate purpose of helping all people live healthy lives," Forlenza said.
The acquisition is subject to regulatory approvals and is expected to close during the third quarter of fiscal year 2011 and the financial terms of the agreement were not disclosed.